跳至主要内容
临床试验/EUCTR2016-001835-11-FR
EUCTR2016-001835-11-FR进行中(未招募)1 期

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer(Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-protocol 01 Revised version 01 dated 08-Apr-2016) - FRACTION-Lung

Bristol-Myers Squibb International Corporation0 个研究点目标入组 295 人开始时间: 2016年11月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
295

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • For the master Protocol :
  • -Advanced Non Small Cell Lung Cancer (NSCLC)
  • -ECOG Performance status of = 1
  • -Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
  • -Must have at least 1 lesion with measurable disease
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 552
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 828

排除标准

  • For the master Protocol :
  • -Subjects with certain mutations must have been treated with a targeted therapy prior to enrollment
  • -Must not have suspected or known central nervous system metastases unless adequately treated
  • -Subjects who need daily oxygen therapy
  • -People with autoimmune disease

研究者

相似试验